Ironwood Pharmaceuticals

Ironwood Pharmaceuticals is an American pharmaceutical company, focuses on the development and commercialization of gastrointestinal (GI) products. Ironwood products used in treatments of cholesterol, gastrointestinal, and cardiovascular diseases, as well as pain, inflammation, and others. The company was founded in 1998 and is headquartered in Boston, Massachusetts.
Ironwood Pharmaceuticals stock price chart
vol.
change
P/E adj.
Net profit (adj.)
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Ironwood Pharmaceuticals balance sheet

Report period2017 2018 2019 2020 2021 2022
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Ironwood Pharmaceuticals cash flows

Report period2017 2018 2019 2020 2021 2022
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
Adjusted Earnings
EBITDA
Adjusted EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS
Adjusted EPS

Ironwood Pharmaceuticals multipliers

Report period2017 2018 2019 2020 2021 2022
P/E
P/E adj.
E/P
E adj./P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
Net Debt/EBITDA adj.
EV/EBITDA
EV/EBITDA adj.

Ironwood Pharmaceuticals profitability

Report period2017 2018 2019 2020 2021 2022
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Ironwood Pharmaceuticals assets
Ironwood Pharmaceuticals cash flows

Ironwood Pharmaceuticals dividend policy

The company doesn't provide dividend

Ironwood Pharmaceuticals shares

TickerNameTypeNominal valueISINPrice
IRWD:USIronwood PharmaceuticalsCommon share-US46333X1081$4.66
Ironwood Pharmaceuticals news
05.05.2022
Ironwood Pharmaceuticals' GAAP net income for 3 months of 2022 was $38.801 million, down 2.8% from $39.926 million in the prior year. Revenue increased 9.8% to $97.529 million from $88.845 million a year earlier.
Source: {source} pictogram investor.ironwoodpharma.com
Pictogram next
17.02.2022
Ironwood Pharmaceuticals' GAAP net income for 2021 was $528.448 million, up 4.97 times from $106.176 million in the previous year. Revenue increased 6.2% to $413.753 million from $389.523 million a year earlier.
Source: {source} pictogram investor.ironwoodpharma.com
Pictogram next
04.11.2021
Ironwood Pharmaceuticals' GAAP net income for 9M 2021 was $487.074 million, up 7.7 times from $62.972 million in the previous year. Revenue increased 8.7% to $296.623 million from $272.843 million a year earlier.
Source: {source} pictogram investor.ironwoodpharma.com
Pictogram next
05.08.2021
Ironwood Pharmaceuticals' GAAP net income for six months of 2021 was $431.229 million, up 15 times from $28.549 million in the previous year. Revenue increased 13.9% to $192.876 million from $169.375 million a year earlier.
Source: {source} pictogram investor.ironwoodpharma.com
Pictogram next
All Ironwood Pharmaceuticals news
General information
Company nameIronwood Pharmaceuticals
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Pharmaceuticals / Pharmaceuticals
Business address301 Binney Street Cambridge, MA 02142 United States
Mailing address301 Binney Street Cambridge, MA 02142 United States
Websiteinvestor.ironwoodpharma.com
Information disclosurewww.sec.gov